Bevacizumab FDA approval date

The FDA approved Bevacizumab (Avastin) on 26 Feb 2004.

FDA approval date
26 Feb 2004

Drug identity checked against registry records

Also recorded as Avastin

Included trials

TrialSponsorPhaseStatusPrimary completion
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal CancerNCT07446322Oncolytics BiotechPhase 2Recruiting2027-08-30Estimated
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive GlioblastomaNCT06061809IBRXPhase 2Active not recruiting2029-12-31Estimated
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) MutationNCT05593328Cardiff OncologyPhase 2Completed2024-12-09Actual
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCCNCT05733598Replimune, Inc.Phase 2Recruiting2027-12-01Estimated
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS MutationNCT06106308Cardiff OncologyPhase 2Active not recruiting2027-04-16Estimated
A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic TherapyNCT06680258Tempest TherapeuticsPhase 3Not yet recruiting2028-12Estimated
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular CarcinomaNCT06679985CHRSPhase 2Active not recruiting2027-09Estimated
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal CancerNCT03929666Jazz PharmaceuticalsPhase 2Completed2025-08-30Actual
Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular CarcinomaNCT05359861CHRSPhase 2Terminated2025-06-30Actual

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2004-02-26DayBevacizumabFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "BLA125085", "applicant_as_listed_by_fda": "GENENTECH", "brand_names": ["AVASTIN"], "active_ingredients": ["BEVACIZUMAB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20040226", "matched_on": "drug name equals FDA sole active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026